Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014
| Autor: | Clement Lingani, Mamoudou Harouna Djingarey, Denis Kandolo, Ryan T. Novak, William Perea, Rodrigue Barry, Fabien Diomandé, Carol Tevi-Benissan, Florence Shirehwa, Marie-Pierre Preziosi, F. Marc LaForce |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Microbiology (medical)
Population The Meningitis Vaccine Project: The Development Licensure Introduction and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Meningococcal Vaccines Meningococcal vaccine Meningitis Meningococcal meningitis belt parasitic diseases medicine Disease Transmission Infectious Humans Socioeconomics education Africa South of the Sahara education.field_of_study Vaccines Conjugate business.industry Immunization Programs Vaccination The Development Licensure and Introduction of Menafrivac medicine.disease Virology Infectious Diseases Vaccination Campaigns Immunization PsA-TT Africa rollout plan African meningitis belt Meningococcal conjugate vaccine meningococcal group A business Meningitis |
| Zdroj: | Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |
| ISSN: | 1537-6591 |
| Popis: | Background. A group A meningococcal conjugate vaccine (PsA-TT) was developed specifically for the African “meningitis belt” and was prequalified by the World Health Organization (WHO) in June 2010. The vaccine was first used widely in Burkina Faso, Mali, and Niger in December 2010 with great success. The remaining 23 meningitis belt countries wished to use this new vaccine. Methods. With the help of African countries, WHO developed a prioritization scheme and used or adapted existing immunization guidelines to mount PsA-TT vaccination campaigns. Vaccine requirements were harmonized with the Serum Institute of India, Ltd. Results. Burkina Faso was the first country to fully immunize its 1- to 29-year-old population in December 2010. Over the next 4 years, vaccine coverage was extended to 217 million Africans living in 15 meningitis belt countries. Conclusions. The new group A meningococcal conjugate vaccine was well received, with country coverage rates ranging from 85% to 95%. The rollout proceeded smoothly because countries at highest risk were immunized first while attention was paid to geographic contiguity to maximize herd protection. Community participation was exemplary. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|